Karin Briner
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Karin Briner.
Tetrahedron Letters | 2001
Christophe Morice; Mathias Domostoj; Karin Briner; André Mann; Jean Suffert; Camille-Georges Wermuth
Two intramolecular routes were experimented to reach the hexahydrobenzofuro(2,3-c)pyridine platform: a Heck and a radical reaction. The radical route was applicable to all substrates, whereas the Heck route was of limited use. The key adducts were obtained via a Mitsunobu condensation between halogenated phenols and an allylic alcohol, the 3-hydroxy-tetra- hydropyridine.
Frontiers in Psychiatry | 2017
Michelle M. Rodriguez; Carl D. Overshiner; J. David Leander; Xia Li; Denise Morrow; Richard G Conway; David L. Nelson; Karin Briner; Jeffrey M. Witkin
Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive–compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclinical and clinical findings have suggested serotonin2C (5-HT2C) receptors as a potential drug target. Data in rats and mice are presented here on the effects of a novel 5-HT2C receptor agonist ((3S)-3-Methyl-1-[4-(trifluoromethyl)-7-benzofuranyl]-piperazine) (CPD 1) with high potency and full efficacy at 5-HT2C receptors and less potency and partial agonism at 5-HT2A and 5-HT2B receptors. Effects of CPD 1 on consummatory (schedule-induced polydipsia in rats) and non-consummatory behaviors (marble-burying and nestlet-shredding in mice) that are repetitive and non-habituating were studied. We also evaluated the effects of CPD 1 in rats with isoproterenol- and deprivation-induced drinking in rats to compare with the polydipsia studies. The SSRIs, fluoxetine, and chlomipramine decreased the high rates of drinking in rats engendered by a schedule of intermittent food delivery (schedule-induced polydipsia). The effects of fluoxetine, but not of d-amphetamine, were prevented by the selective 5-HT2C receptor antagonist SB242084. The 5-HT2C receptor agonists Ro 60-0175 and CPD 1 also decreased drinking, but unlike the SSRIs and Ro 60-0175, CPD 1 dose-dependently decreased excessive drinking without affecting lever press responses that produced food. The effects of CPD 1 were prevented by SB242084. CPD 1 also suppressed drinking induced by isoproterenol and by water deprivation without affecting normative drinking behavior. CPD 1, like fluoxetine, also suppressed marble-burying and nestlet-shredding in mice at doses that did not affect rotarod performance or locomotor activity. The behavioral specificity of effects of CPD 1 against repetitive and excessive behaviors suggests a potential therapeutic application in OCD.
Archive | 2000
Karin Briner; Joseph Paul Burkhart; Timothy Paul Burkholder; Brian Eugene Cunningham; Matthew Joseph Fisher; William Harlan Gritton; Shawn Christopher Miller; Jeffrey Thomas Mullaney; Matthew Robert Reinhard; Dennis Charles Thompson; Leonard L. Winneroski; Yanping Xu
Archive | 2002
Karin Briner; Christopher William Doecke; Vincent Mancuso; Michael John Martinelli; Timothy I. Richardson; Roger Ryan Rothhaar; Qing Shi; Chaoyu Xie
Archive | 2002
Ryan T. Backer; Karin Briner; Christopher William Doecke; Matthew Joseph Fisher; Steven L. Kuklish; Vincent Mancuso; Michael J. Martinelli; Jeffrey Thomas Mullaney; Chaoyu Xie
Journal of Medicinal Chemistry | 2004
Timothy I. Richardson; Paul L. Ornstein; Karin Briner; Matthew Joseph Fisher; Ryan T. Backer; C. Kelly Biggers; Michael P. Clay; Paul J. Emmerson; Larry Wayne Hertel; Hansen M. Hsiung; Saba Husain; Steven D. Kahl; Jonathan A. Lee; Terry D. Lindstrom; Michael J. Martinelli; John P. Mayer; Jeffery T. Mullaney; Thomas P. O'brien; Joseph Matthew Pawlak; Kevin D. Revell; Jikesh Shah; John M. Zgombick; R. Jason Herr; Alex Melekhov; Peter B. Sampson; Chi-Hsin R. King
Archive | 2006
John Gordon Allen; Karin Briner; Anne Marie Camp; Manuel Javier Cases-Thomas; Richard Charles Hoying; Maria Angeles Martinez-Grau; Michael Philip Mazanetz; Natalia Pokrovskaia; Richard Edmund Rathmell; Roger Ryan Rothhaar; Selma Sapmaz; Andrew Caerwyn Williams
Archive | 2000
Karin Briner; Joseph Paul Burkhart; Timothy Paul Burkholder; Matthew Joseph Fisher; William Harlan Gritton; Daniel Timothy Kohlman; Sidney Xi Liang; Shawn Christopher Miller; Jeffrey Thomas Mullaney; Yao-Chang Xu; Yanping Xu
Bioorganic & Medicinal Chemistry Letters | 2005
Matthew Joseph Fisher; Ryan T. Backer; Saba Husain; Hansen M. Hsiung; Jeffrey Thomas Mullaney; Thomas P. O’Brian; Paul L. Ornstein; Roger Ryan Rothhaar; John M. Zgombick; Karin Briner
Bioorganic & Medicinal Chemistry Letters | 2006
Qing Shi; Paul L. Ornstein; Karin Briner; Timothy I. Richardson; Macklin Brian Arnold; Ryan T. Backer; Jennifer L. Buckmaster; Emily J. Canada; Christopher W. Doecke; Larry Wayne Hertel; Nick Honigschmidt; Hansen M. Hsiung; Saba Husain; Steve L. Kuklish; Michael J. Martinelli; Jeffrey Thomas Mullaney; Thomas P. O’Brien; Matt R. Reinhard; Roger Ryan Rothhaar; Jikesh Shah; Zhipei Wu; Chaoyu Xie; John M. Zgombick; Matthew Joseph Fisher